Health News Archive - May 25, 2009
- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints - NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab) continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis (RA).
KUALA LUMPUR, Malaysia, May 25 /PRNewswire/ -- While the economic recession poses great challenges for the global industries to handle, the healthcare delivery market remains as one of the few recession proof sectors, alongside education and entertainment industries.
Eighteen US soldiers confirmed as having the swine flu are fully recovered after being treated on an American base in Kuwait.
After a week-long conference in Geneva, the World Health Organizationâ€™s Margaret Chan said on Friday that health authorities around the world should prepare themselves for a rise in both the number and severity of H1N1 swine flu cases in the coming months.
It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone's advantage.
An emerging form of the pathogenic yeast Candida is able to complete a full sexual cycle in a test tube, even though it's missing the genes for reproduction. And it may also do so while infecting us, according to Duke University Medical Center researchers.
Using a specially adapted tool called P[acman], a collaboration of researchers led by Baylor College of Medicine has established a library of clones that cover most of the genome of Drosophila melanogaster (fruit fly) and should speed the pace of genetic research.
Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.
- Initial U.S. order for bulk vaccine valued at $190 million - SWIFTWATER, Pa.
UPPSALA, Sweden, May 25 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ: CBST).